Crossmark

Modified albumin–bilirubin grade to predict eligibility for second-line therapies at progression on sorafenib therapy in hepatocellular carcinoma patients

Crossref DOI link: https://doi.org/10.1007/s10147-020-01835-2

Published Online: 2021-03-17

Published Print: 2021-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tokunaga, Takayuki

Tanaka, Motohiko

Tanaka, Kentaro

Narahara, Satoshi

Kawasaki, Takeshi

Yoshimaru, Yoko

Nagaoka, Katsuya

Watanabe, Takehisa

Tateyama, Masakuni

Naoe, Hideaki

Sasaki, Yutaka

Tanaka, Yasuhito
License Information

Text and Data Mining valid from 2021-03-17

Version of Record valid from 2021-03-17
More Information

Article History

Received: 21 July 2020

Accepted: 2 November 2020

First Online: 17 March 2021

Compliance with ethical standard

:

: The authors have no conflicts of interest to declare.

Document is current

Any future updates will be listed below